Use of the A 2A adenosine receptor as a physiological immunosuppressor and to engineer inflammation in vivo

Biochemical Pharmacology

Volumn 65, Issue 4, 2003, Pages 493-501

  Sitkovsky, Michail V ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Adenosine; Cancer immunotherapy; Cytokines; Engineering; Inflammation; Tissue damage

Indexed keywords

ADENOSINE; ADENOSINE A2A RECEPTOR; ADENOSINE A2A RECEPTOR AGONIST; ADENOSINE A2A RECEPTOR ANTAGONIST; ANTIINFLAMMATORY AGENT; CYCLIC AMP; PURINE RECEPTOR;

AUTOIMMUNE DISEASE; BIOACCUMULATION; BIOENGINEERING; DRUG RESEARCH; DRUG TARGETING; HUMAN; HYPOXIA; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; IN VIVO STUDY; INFLAMMATION; METABOLISM; MOLECULAR RECOGNITION; MOLECULE; NEGATIVE FEEDBACK; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; REVIEW; SEPSIS; SIGNAL TRANSDUCTION; TISSUE INJURY; TUMOR;

EID: 0037441343     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(02)01548-4     Document Type: Note

References (113)

1. Niklason L.E., Langer R. Prospects for organ and tissue replacement. JAMA. 285:2001;573-576.
2. Griffith L.G., Naughton G. Tissue engineering - current challenges and expanding opportunities. Science. 295:2002;1009-1014.
3. Rosenberg HF, Gallin JI. Inflammation. In: Paul WE, editor. Fundamental immunology. Philadelphia: Lippincott-Raven; 1999. p. 1051-62.
4. Shacter E, Weitzman SA. Chronic inflammation and cancer. Oncology (Huntingt) 2002;16:217-26, 229; discussion 230-2.
5. 2A receptor stimulation reduces inflammation and neointimal growth in a murine carotid ligation model. Arterioscler. Thromb. Vasc. Biol. 21:2001;791-796.
6. Pockley A.G. Heat shock proteins, inflammation, and cardiovascular disease. Circulation. 105:2002;1012-1017.
7. Shebuski R.J., Kilgore K.S. Role of inflammatory mediators in thrombogenesis. J. Pharmacol. Exp. Ther. 300:2002;729-735.
8. Mulvihill N.T., Foley J.B. Inflammation in acute coronary syndromes. Heart. 87:2002;201-204.
9. Levy B.D., Clish C.B., Schmidt B., Gronert K., Serhan C.N. Lipid mediator class switching during acute inflammation: signals in resolution. Nat. Immunol. 2:2001;612-619.
10. Aliberti J., Hieny S., Reis e Sousa C., Serhan C.N., Sher A. Lipoxin-mediated inhibition of IL-12 production by DCs: a mechanism for regulation of microbial immunity. Nat. Immunol. 3:2002;76-82.
11. Ohta A., Sitkovsky M. Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature. 414:2001;916-920.
12. 2A agonists. J. Pharmacol. Exp. Ther. 298:2001;209-218.
13. β4 . Mol. Pharmacol. 61:2002;455-462.
14. 3 adenosine receptor antagonists. J. Med. Chem. 45:2002;770-780.
15. 3 receptor with selectively enhanced affinity for amine-modified nucleosides. J. Med. Chem. 44:2001;4125-4136.
16. 2A receptor agonists. Br. J. Pharmacol. 132:2001;1017-1026.
17. Cassada D.C., Tribble C.G., Kaza A.K., Fiser S.M., Long S.M., Linden J., Rieger J.M., Kron I.L., Kern J.A. Adenosine analogue reduces spinal cord reperfusion injury in a time-dependent fashion. Surgery. 130:2001;230-235.
18. Schijns V.E. Induction and direction of immune responses by vaccine adjuvants. Crit. Rev. Immunol. 21:2001;75-85.
19. Chambers C.A., Kuhns M.S., Egen J.G., Allison J.P. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu. Rev. Immunol. 19:2001;565-594.
20. Deuticke B., Gerlach E., Diekesmann R. Decomposition of free nucleotides in the rat heart, skeletal muscle, brain and liver in oxygen deficiency. Pflugers Arch. Gesamte Physiol. Menschen. Tiere. 292:1966;239-254.
21. Burnstock G., Campbell G., Satchell D., Smythe A. Evidence that adenosine triphosphate or a related nucleotide is the transmitter substance released by non-adenergic inhibitory nerves in the gut. Br. J. Pharmacol. 40:1970;668-688.
22. Shimizu H., Creveling C.R., Daly J. Stimulated formation of adenosine 3′,5′-cyclic phosphate in cerebral cortex: synergism between electrical activity and biogenic amines. Proc. Natl. Acad. Sci. U.S.A. 65:1970;1033-1040.
23. 14 C ]adenine and derivatives by cerebral tissues, superfused and electrically stimulated Biochem. J. 126:1972;965-973.
24. Berne R.M., Rubio R. Regulation of coronary blood flow. Adv. Cardiol. 12:1974;303-317.
25. Bockman E.L., Berne R.M., Rubio R. Release of adenosine and lack of release of ATP from contracting skeletal muscle. Pflugers Arch. 355:1975;229-241.
26. Sullivan T.J., Parker C.W. Pharmacologic modulation of inflammatory mediator release by rat mast cells. Am. J. Pathol. 85:1976;437-464.
27. Marquardt D.L., Gruber H.E., Wasserman S.I. Adenosine release from stimulated mast cells. Proc. Natl. Acad. Sci. U.S.A. 81:1984;6192-6196.
28. Filippini A., Taffs R.E., Sitkovsky M.V. Extracellular ATP in T-lymphocyte activation: possible role in effector functions. Proc. Natl. Acad. Sci. U.S.A. 87:1990;8267-8271.
29. 2 receptor on human neutrophils. J. Immunol. 135:1985;1366-1371.
30. Linden J. Molecular approach to adenosine receptors: receptor-mediated mechanisms of tissue protection. Annu. Rev. Pharmacol. Toxicol. 41:2001;775-787.
31. Winn H.R., Rubio R., Berne R.M. Brain adenosine concentrations during hypoxia in rats. Am. J. Physiol. 241:1981;H235-H242.
32. Van Belle H., Goossens F., Wynants J. Formation and release of purine catabolites during hypoperfusion, anoxia, and ischemia. Am. J. Pathol. 252:1987;H886-H893.
33. Rudolphi KA, Shubert P. Adenosine and brain ischemia. Norwell, MA: Kluwer; 1995.
34. Decking U.K.M., Schlieper G., Kroll K., Schrader J. Hypoxia-induced inhibition of adenosine kinase potentiates cardiac adenosine release. Circ. Res. 81:1997;154-164.
35. Hershfield M.S. Adenosine deaminase deficiency: clinical expression, molecular basis, and therapy. Semin. Hematol. 35:1998;291-298.
36. Cronstein B.N. Adenosine, an endogenous anti-inflammatory agent. J. Appl. Physiol. 76:1994;5-13.
37. Capecchi P.L., Ceccatelli L., Beermann U., Laghi Pasini F., Di Perri T. Inhibition of neutrophil function in vitro by nimesulide. Preliminary evidence of an adenosine-mediated mechanism. Arzneimittelforschung. 43:1993;992-996.
38. 2A receptors. Eur. J. Pharmacol. 313:1996;237-242.
39. Born G.V., Honour A.J., Mitchell J.R. Inhibition by adenosine and by 2-chloroadenosine of the formation and embolization of platelet thrombi. Nature. 202:1964;761-765.
40. Lichtenstein L.M., Margolis S. Histamine release in vitro: inhibition by catecholamines and methylxanthines. Science. 161:1968;902-903.
41. Wolberg G., Zimmerman T.P., Hiemstra K., Winston M., Chu L.C. Adenosine inhibition of lymphocyte-mediated cytolysis: possible role of cyclic adenosine monophosphate. Science. 187:1975;957-959.
42. Marone G., Plaut M., Lichenstein L.M. Characterization of a specific adenosine receptor on human lymphocytes. J. Immunol. 121:1978;2153-2159.
43. Marone G., Findlay S.R., Lichtenstein L.M. Adenosine receptor on human basophils: modulation of histamine release. J. Immunol. 123:1979;1473-1477.
44. Fredholm B.B., Fried G., Hedqvist P. Origin of adenosine release from rat vas deferens by nerve stimulation. Eur. J. Pharmacol. 79:1982;233-243.
45. Burnstock G. Purinergic nerves. Pharmacol. Rev. 24:1972;509-581.
46. Jacobson KA, van Rhee AM. Development of selective purinoceptor agonists and antagonists. In: Jacobson KA, Jarvis MF, editors. Purinergic approaches in experimental therapeutics. New York: Wiley; 1997. p. 101-28.
47. Libert F., Parmentier M., Lefort A., Dinsart C., Van Sande J., Maenhaut C., Simons M.J., Dumont J.E., Vassart G. Selective amplification and cloning of four new members of the G protein-coupled receptor family. Science. 244:1989;569-572.
48. Olah M.E., Stiles G.L. Adenosine receptor subtypes: characterization and therapeutic regulation. Annu. Rev. Pharmacol. Toxicol. 35:1995;581-606.
49. q in human embryonic kidney 293 cells and HMC-1 mast cells. Mol. Pharmacol. 56:1999;705-713.
50. 2 receptors stimulate mitogen-activated protein kinase in human embryonic kidney-293 cells. Cross-talk between cyclic AMP and protein kinase C pathways. J. Biol. Chem. 274:1999;5972-5980.
51. 2z -type purinoreceptor during differentiation. J. Immunol. 157:1996;1371-1380.
52. 2U -purinergic nucleotide receptor messenger RNA expression during in vitro differentiation of human myeloid leukocytes by phorbol esters or inflammatory activators. Mol. Pharmacol. 51:1997;97-108.
53. 2 nucleotide receptor mRNA expression is an immediate early gene response in activated thymocytes. Proc. Natl. Acad. Sci. U.S.A. 94:1997;831-836.
54. 2A receptors in human monocytic THP-1 cells. J. Immunol. 167:2001;4026-4032.
55. 2 receptors. J. Immunol. 148:1992;2201-2206.
56. Hoskin D.W., Reynolds T., Blay J. Adenosine as a possible inhibitor of killer T-cell activation in the microenvironment of solid tumours. Int. J. Cancer. 59:1994;854-855.
57. Firestein G.S. Anti-inflammatory effects of adenosine kinase inhibitors in acute and chronic inflammation. Drug Dev. Res. 39:1996;371-376.
58. Hasko G., Szabo C., Nemeth Z.H., Kvetan V., Pastores S.M., Vizi E.S. Adenosine receptor agonists differentially regulate IL-10, TNF-α and nitric oxide production in RAW 264.7 macrophages and in endotoxemic mice. J. Immunol. 157:1996;4634-4640.
59. Eigler A., Greten T.F., Sinha B., Chaslberger C., Sullivan G.W., Enderas S. Endogenous adenosine curtails lipopolysaccharide-stimulated tumour necrosis factor synthesis. Scand. J. Immunol. 45:1997;132-139.
60. Sullivan G.W., Linden J. Role of A2a adenosine receptors in inflammation. Drug Dev. Res. 45:1998;103-112.
61. Apasov S.G., Koshiba M., Chused T.M., Sitkovsky M.V. Effects of extracellular ATP and adenosine on different thymocyte subsets: possible role of ATP-gated channels and G protein-coupled purinergic receptors. J. Immunol. 158:1997;5095-5105.
62. Huang S., Apasov S., Koshiba M., Sitkovsky M. Role of A2a extracellular adenosine receptor-mediated signaling in adenosine-mediated inhibition of T-cell activation and expansion. Blood. 90:1997;1600-1610.
63. 2a purinergic receptor-mediated signaling in murine T cells. J. Biol. Chem. 272:1997;25881-25889.
64. 2A receptor monoclonal antibodies. Mol. Pharmacol. 55:1999;614-624.
65. 3 receptors: pharmacological properties, species differences and receptor functions. Trends Pharmacol. Sci. 15:1994;298-306.
66. Marquardt D.L., Walker L.L., Heinemann S. Cloning of two adenosine receptor subtypes from mouse bone marrow-derived mast cells. J. Immunol. 152:1994;4508-4515.
67. Parmely M.J., Zhou W.-W., Edwards C.K. III, Borcherding D.R., Silverstein R., Morrison D.C. Adenosine and a related carbocyclic nucleoside analogue selectively inhibit tumor necrosis factor-α production and protect mice against endotoxin challenge. J. Immunol. 151:1993;389-396.
68. Bouma M.G., Stad R.K., van den Wildenberg F.A.J.M., Buurman W.A. Differential regulatory effects of adenosine on cytokine release by activated human monocytes. J. Immunol. 153:1994;4159-4168.
69. 3 receptors decreases interleukin-12 and interferon-γ production and prevents lethality in endotoxemic mice. Eur. J. Pharmacol. 358:1998;261-268.
70. 3 receptors on macrophages inhibits tumor necrosis factor-α Eur. J. Pharmacol. 310:1996;209-216.
71. Sajjadi F.G., Takabayashi K., Foster A.C., Domingo R.C., Firestein G.S. Inhibition of TNF-α expression by adenosine. Role of A3 adenosine receptors. J. Immunol. 156:1996;3435-3442.
72. Link A.A., Kino T., Worth J.A., McGuire J.L., Crane M.L., Chrousos G.P., Wilder R.L., Elenkov I.J. Ligand-activation of the adenosine A2a receptors inhibits IL-12 production by human monocytes. J. Immunol. 164:2000;436-442.
73. 2a receptor. Nature. 388:1997;674-678.
74. 2A adenosine receptor deficiency attenuates brain injury induced by transient focal ischemia in mice. J. Neurosci. 19:1999;9192-9200.
75. 3 adenosine receptor gene in mice and its effect on stimulated inflammatory cells. J. Biol. Chem. 275:2000;4429-4434.
76. Essayan D.M. Cyclic nucleotide phosphodiesterase (PDE) inhibitors and immunomodulation. Biochem. Pharmacol. 57:1999;965-973.
77. Torgersen K.M., Vang T., Abrahamsen H., Yaqub S., Tasken K. Molecular mechanisms for protein kinase A-mediated modulation of immune function. Cell Signal. 14:2002;1-9.
78. Gilman A.G. G proteins: transducers of receptor-generated signals. Annu. Rev. Biochem. 56:1987;615-649.
79. + T and B lymphocyte function in vitro and in vivo. Pharmacol. Rev. 53:2001;487-525.
80. Abbracchio M.P., Burnstock G. Purinergic signalling: pathophysiological roles. Jpn. J. Pharmacol. 78:1998;113-145.
81. Harris S.G., Padilla J., Koumas L., Ray D., Phipps R.P. Prostaglandins as modulators of immunity. Trends Immunol. 23:2002;144-150.
82. Trenn G., Takayama H., Sitkovsky M.V. Exocytosis of cytolytic granules may not be required for target cell lysis by cytotoxic T-lymphocytes. Nature. 330:1987;72-74.
83. Takayama H., Sitkovsky M.V. Antigen receptor-regulated exocytosis in cytotoxic T lymphocytes. J. Exp. Med. 166:1987;725-743.
84. Takayama H., Trenn G., Sitkovsky M.V. Locus of inhibitory action of cAMP-dependent protein kinase in the antigen-receptor triggered cytotoxic T-lymphocyte activation pathway. J. Biol. Chem. 263:1988;2330-2336.
85. 2+ ionophores. Proc. Natl. Acad. Sci. U.S.A. 84:1987;1364-1368.
86. Kincaid R.L., Takayama H., Billingsley M.L., Sitkovsky M.V. Differential expression of calmodulin-binding proteins in B, T lymphocytes and thymocytes. Nature. 330:1987;176-178.
87. Filippini A., Taffs R.E., Agui T., Sitkovsky M.V. Ecto-ATPase activity in cytolytic T-lymphocytes. Protection from the cytolytic effects of extracellular ATP. J. Biol. Chem. 265:1990;334-340.
88. diVirgilio F., Pizzo P., Zanovello P., Bronte V., Collavo D. Extracellular ATP as a possible mediator of cell-mediated cytotoxicity. Immunol. Today. 11:1990;274-277.
89. Burnstock G. Purine-mediated signaling in pain and visceral perception. Trends Pharmacol. Sci. 22:2001;182-188.
90. Fredholm B.B., Arslan G., Halldner L., Kull B., Schulte G., Wasserman W. Structure and function of adenosine receptors and their genes. Naunyn Schmiedebergs Arch. Pharmacol. 362:2000;364-374.
91. 2+ and pH. J. Immunol. 147:1991;3638-3645.
92. 2A receptor independent effects of extracellular adenosine on murine thymocytes in conditions of adenosine deaminase deficiency. Blood. 95:2000;3859-3867.
93. 2A receptor-unrelated lymphotoxicity. Br. J. Pharmacol. 131:2000;43-50.
94. 2A receptor gene-deficient mice. Biochem. J. 354:2001;123-130.
95. Apasov S.G., Blackburn M.R., Smith P.T., Kellems R.E., Sitkovsky M.V. Adenosine deaminase deficiency in mice increases thymic apoptosis and causes defective T cell receptor signaling. J. Clin. Invest. 108:2001;131-141.
96. 2A -adenosine receptor activation and PDE 4 inhibition. Kidney Int. 59:2001;2114-2125.
97. Peart J., Flood A., Linden J., Matherne G.P., Headrick J.P. Adenosine-mediated cardioprotection in ischemic-reperfused mouse heart. J. Cardiovasc. Pharmacol. 39:2002;117-129.
98. Ross S.D., Tribble C.G., Linden J., Gangemi J.J., Lanpher B.C., Wang A.Y., Kron I.L. Selective adenosine-A2A activation reduces lung reperfusion injury following transplantation. J. Heart Lung Transplant. 18:1999;994-1002.
99. 2A adenosine receptor activation reduces skin pressure ulcer formation and inflammation. Am. J. Physiol. Heart Circ. Physiol. 281:2001;H67-H74.
100. Melmon K.L., Rocklin R.E., Rosenkranz R.P. Autacoids as modulators of the inflammatory and immune response. Am. J. Med. 71:1981;100-106.
101. Bourne H.R., Melmon K.L. Adenyl cyclase in human leukocytes: evidence for activation by separate beta adrenergic and prostaglandin receptors. J. Pharmacol. Exp. Ther. 178:1971;1-7.
102. 2 receptor agonist AMP 579 in a porcine model of myocardial infarction. J. Pharmacol. Exp. Ther. 286:1998;611-618.
103. 2 receptor activation attenuates reperfusion injury by inhibiting neutrophil accumulation, superoxide generation and coronary endothelial adherence. J. Pharmacol. Exp. Ther. 280:1997;301-309.
104. 2A adenosine receptor agonists. J. Med. Chem. 44:2001;531-539.
105. 2A adenosine receptor-mediated inhibition of renal injury and neutrophil adhesion. Am. J. Physiol. Renal Physiol. 279:2000;F809-F818.
106. 2 generation, respectively. J. Clin. Invest. 85:1990;1150-1157.
107. 3 adenosine receptors and stimulates mast cell degranulation. J. Clin. Invest. 100:1997;2849-2857.
108. Moser G.H., Schrader J., Deussen A. Turnover of adenosine in plasma of human and dog blood. Am. J. Physiol. 256:1989;C799-C806.
109. 2A adenosine receptor inhibits inflammation in a rat model of meningitis: synergy with the type IV phosphodiesterase inhibitor, rolipram. J. Infect. Dis. 180:1999;1550-1560.
110. 3 adenosine receptor is the unique adenosine receptor which facilitates release of allergic mediators in mast cells. J. Biol. Chem. 268:1993;16887-16890.
111. Schwartz L.M., Raschke P., Becker B.F., Gerlach E. Adenosine contributes to neutrophil-mediated loss of myocardial function in post-ischemic guinea-pig hearts. J. Mol. Cell. Cardiol. 25:1993;927-938.
112. Semenza G.L. HIF-1: mediator of physiological and pathophysiological responses to hypoxia. J. Appl. Physiol. 88:2000;1474-1480.
113. Lukashev D., Caldwell C., Ohta A., Chen P., Sitkovsky M. Differential regulation of two alternatively spliced isoforms of hypoxia-inducible factor-1α in activated T lymphocytes. J. Biol. Chem. 276:2001;48754-48763.